|
|
Merck and Schering-Plough, makers
of Zetia, announced that the drug had failed to benefit
patients in a two-year trial that ended in April 2006.
In a press release, Merck and Schering said that not
only did Zetia fail to slow the accumulation of fatty
plaque in the arteries, it actually seemed to contribute
to plaque formation — although by such a small
amount that the finding could have been a result of
chance.
Dr. Steven E. Nissen, the chairman
of cardiology at the Cleveland Clinic, said
the results were “shocking.” “This is as bad a result for the
drug as anybody could have feared,” said Dr. Nissen, a widely published
researcher and senior consulting editor to the Journal of the American College
of Cardiology. Millions of patients may be taking a drug that does not benefit
them, raising their risk of heart attacks and exposing them to potential side
effects, he said. Patients should not be given prescriptions for Zetia unless
all other cholesterol drugs have failed, he said.
Source: Study
Reveals Doubt on Drug for Cholesterol (NY Times, January 15, 2008).
|
|
All contents Copyright © 2008 Tango Advanced Nutrition, Inc. All rights reserved. AllerPhase®, ArthriPhase™, BronchoPhase®, CardioPhase®, Daily Movement™, FemmePhase®, Herbal Boost™, ImmunoPhase®, MetaPhase®, OsteoPhase®, PriaPlex®, Pure Tango®, SleepCycle™, Tango® and Vital Cell® are registered trademarks of Tango Advanced Nutrition, Inc. The content provided by this site is for informational purposes only and has not been approved by the U.S. FDA. This site is not intended to provide personal medical advice, which should be obtained from a medical professional.
|
|
|
